Another experimental COVID-19 drug is approved to treat severe cases of COVID-19 infection
Regeneron
is the latest pharma company to receive the Food and Drug Administration’s
emergency use authorization for its experimental COVID-19 vaccine.
The company was granted a EUA for the same drug that
President Trump was administrated when he was declared positive for infection.
Multiple studies showed that the drug is effective when it is
administrated shortly after diagnosis. Now, it will be used in severe cases of
infection.
Regeneron has doses to treat 80,000 patients by the end of
November, and the number will increase to 300,000 by the end of January 2021.
According to data from Johns Hopkins, the US has the largest
death toll, with more than 12 million confirmed cases.
Following the news, Regeneron stock price traded 3.9%
higher.
Sources: bbc.com
This information prepared by ClickTrades.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of ClickTrades.com.
Previous Article
Macy’s doesn’t impress with its Q3 results
Next Article
Tiffany performed better-than-expected in Q3
